Proteomic strategies and challenges in tumor metastasis research

Clinical and Experimental Metastasis

Volumn 27, Issue 6, 2010, Pages 441-451

  Hudler, Petra ^a   Gorsic, Masa ^a   Komel, Radovan ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

2D electrophoresis; Cancer; Mass spectrometry; Metastases; Protein microarrays; Proteomics; Tumor biomarkers

Indexed keywords

CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; DISEASE MARKER; FUNCTIONAL PROTEOMICS; HUMAN; MASS SPECTROMETRY; METASTASIS; PROTEIN MICROARRAY; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS; BIOLOGY; GENETICS; METHODOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEOMICS;

TUMOR MARKER;

COMPUTATIONAL BIOLOGY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; MASS SPECTROMETRY; NEOPLASM METASTASIS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955865145     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-010-9339-7     Document Type: Review

References (93)

1. E Fokas, et al. 2007 Metastasis: the seed and soil theory gains identity Cancer Metastasis Rev 26 3-4 705 715 10.1007/s10555-007-9088-5 17786535
2. K Pantel RH Brakenhoff B Brandt 2008 Detection, clinical relevance and specific biological properties of disseminating tumour cells Nat Rev Cancer 8 5 329 340 10.1038/nrc2375 1:CAS:528:DC%2BD1cXltVGlurs%3D 18404148
3. E Sahai 2005 Mechanisms of cancer cell invasion Curr Opin Genet Dev 15 1 87 96 10.1016/j.gde.2004.12.002 1:CAS:528:DC%2BD2MXmvFertw%3D%3D 15661538
4. IJ Fidler 2003 The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited Nat Rev Cancer 3 6 453 458 10.1038/nrc1098 1:CAS:528:DC%2BD3sXktFOnsbg%3D 12778135
5. RR Langley IJ Fidler 2007 Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis Endocr Rev 28 3 297 321 10.1210/er.2006-0027 1:CAS:528:DC%2BD2sXmsVGlu74%3D 17409287
6. YR Chen, et al. 2006 Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells J Proteome Res 5 10 2727 2742 10.1021/pr060212g 1:CAS:528:DC%2BD28XpsF2hsbg%3D 17022644
7. JA Ludwig JN Weinstein 2005 Biomarkers in cancer staging, prognosis and treatment selection Nat Rev Cancer 5 11 845 856 10.1038/nrc1739 1:CAS:528:DC%2BD2MXht1WitLbP 16239904
8. M Polanski NL Anderson 2006 A list of candidate cancer biomarkers for targeted proteomics Biomark Insights 2 1 48
9. WC Cho 2007 Contribution of oncoproteomics to cancer biomarker discovery Mol Cancer 6 25 10.1186/1476-4598-6-25 17407558
10. GS Omenn 2006 Strategies for plasma proteomic profiling of cancers Proteomics 6 20 5662 5673 10.1002/pmic.200600331 1:CAS:528:DC%2BD28XhtFyms7fL 16991194
11. V Zieglschmid C Hollmann O Bocher 2005 Detection of disseminated tumor cells in peripheral blood Crit Rev Clin Lab Sci 42 2 155 196 10.1080/10408360590913696 1:CAS:528:DC%2BD2MXisl2kurc%3D 15941083
12. S Kumar A Mohan R Guleria 2006 Biomarkers in cancer screening, research and detection: present and future: a review Biomarkers 11 5 385 405 10.1080/13547500600775011 1:CAS:528:DC%2BD28Xht1Kmsr7N 16966157
13. A Alaiya M Al-Mohanna S Linder 2005 Clinical cancer proteomics: promises and pitfalls J Proteome Res 4 4 1213 1222 10.1021/pr050149f 1:CAS:528: DC%2BD2MXlsVeks70%3D 16083271
14. WC Cho CH Cheng 2007 Oncoproteomics: current trends and future perspectives Expert Rev Proteomics 4 3 401 410 10.1586/14789450.4.3.401 1:CAS:528:DC%2BD2sXmtFOhtLg%3D 17552924
15. S Ciordia V de Los Rios JP Albar 2006 Contributions of advanced proteomics technologies to cancer diagnosis Clin Transl Oncol 8 8 566 580 10.1007/s12094-006-0062-4 1:CAS:528:DC%2BD28XhtVKju7bM 16952845
16. SM Hanash SJ Pitteri VM Faca 2008 Mining the plasma proteome for cancer biomarkers Nature 452 7187 571 579 10.1038/nature06916 1:CAS:528: DC%2BD1cXktFCgt7g%3D 18385731
17. SA Mani, et al. 2008 The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 133 4 704 715 10.1016/j.cell.2008.03. 027 1:CAS:528:DC%2BD1cXmsVOru7w%3D 18485877
18. K Pankova, et al. 2010 The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells Cell Mol Life Sci 67 1 63 71 10.1007/s00018-009-0132-1 1:CAS:528:DC%2BC3cXis1Wqug%3D%3D 19707854
19. PS Steeg 2006 Tumor metastasis: mechanistic insights and clinical challenges Nat Med 12 8 895 904 10.1038/nm1469 1:CAS:528:DC%2BD28Xnsl2iu74%3D 16892035
20. P Paterlini-Brechot NL Benali 2007 Circulating tumor cells (CTC) detection: clinical impact and future directions Cancer Lett 253 2 180 204 10.1016/j.canlet.2006.12.014 1:CAS:528:DC%2BD2sXnsFKqs7Y%3D 17314005
21. SC Steiniger, et al. 2008 Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population Stem Cells 26 12 3037 3046 10.1634/stemcells.2008-0397 1:CAS:528:DC%2BD1MXhtFSktrc%3D 18802034
22. JM Rosen CT Jordan 2009 The increasing complexity of the cancer stem cell paradigm Science 324 5935 1670 1673 10.1126/science.1171837 1:CAS:528:DC%2BD1MXnsFOmtb8%3D 19556499
23. JP Sullivan JD Minna JW Shay 2010 Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy Cancer Metastasis Rev 29 1 61 72 10.1007/s10555-010-9216-5 20094757
24. J Lu, et al. 2010 Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients Int J Cancer 126 3 669 683 10.1002/ijc.24814 1:CAS:528:DC%2BD1MXhsFGjs7fK 19662651
25. Faca V, Krasnoselsky A, Hanash S (2007) Innovative proteomic approaches for cancer biomarker discovery. Biotechniques 43(3):279, 281-283, 285
26. E Petricoin, et al. 2004 Clinical proteomics: revolutionizing disease detection and patient tailoring therapy J Proteome Res 3 2 209 217 10.1021/pr049972m 1:CAS:528:DC%2BD2cXhs1yhsr0%3D 15113096
27. MS Pepe, et al. 2001 Phases of biomarker development for early detection of cancer J Natl Cancer Inst 93 14 1054 1061 10.1093/jnci/93.14.1054 1:STN:280:DC%2BD3MvgvVWmsw%3D%3D 11459866
28. National Comprehensive Cancer Network I (2007) NCCN clinical practice guidelines in oncology: prostate cancer v.1.2007
29. American Cancer Society. Tumor Markers. http://www.cancer.org/Treatment/ UnderstandingYourDiagnosis/ExamsandTestDescriptions/TumorMarkers/. Accessed 2 Jan 2010
30. M Lu, et al. 2007 Proteomics and mass spectrometry for cancer biomarker discovery Biomark Insights 2 347 360 19662217
31. H Mischak, et al. 2009 Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments Mass Spectrom Rev 28 5 703 724 10.1002/mas.20205 1:CAS:528:DC%2BD1MXhtFaisbzM 18973238
32. Van Eyk JE, Dunn MJ (2008) Clinical proteomics: from diagnosis to therapy. Wiley-VCH, Weinheim
33. LA Liotta EF Petricoin 2006 Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold J Clin Invest 116 1 26 30 10.1172/JCI27467 1:CAS:528:DC%2BD28XjslOisw%3D%3D 16395400
34. GS Omenn, et al. 2005 Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database Proteomics 5 13 3226 3245 10.1002/pmic.200500358 1:CAS:528:DC%2BD2MXps12it7s%3D 16104056
35. P de la Grange, et al. 2010 Splicing factor and exon profiling across human tissues Nucleic Acids Res 38 9 2825 2838 10.1093/nar/gkq008 20110256
36. M Dutertre, et al. 2010 Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis Cancer Res 70 3 896 905 10.1158/0008-5472.CAN-09-2703 1:CAS:528:DC%2BC3cXht12qsr8%3D 20103641
37. X Qu T Komatsu 2010 Molecular capture in protein nanotubes ACS Nano 4 1 563 573 10.1021/nn901474y 1:CAS:528:DC%2BD1MXhsFyit7vF 20020754
38. SE Warder, et al. 2009 Reducing agent-mediated precipitation of high-abundance plasma proteins Anal Biochem 387 2 184 193 10.1016/j.ab.2009.01. 013 1:CAS:528:DC%2BD1MXjt1Kmu7g%3D 19454248
39. X Fang WW Zhang 2008 Affinity separation and enrichment methods in proteomic analysis J Proteomics 71 3 284 303 10.1016/j.jprot.2008.06.011 1:CAS:528:DC%2BD1cXhtVSiu7zO 18619565
40. V Polaskova, et al. 2010 High-abundance protein depletion: comparison of methods for human plasma biomarker discovery Electrophoresis 31 3 471 482 10.1002/elps.200900286 1:CAS:528:DC%2BC3cXhtl2isbc%3D 20119956
41. A Luchini, et al. 2010 Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery Curr Mol Med 10 2 133 141 10.2174/156652410790963268 1:CAS:528:DC%2BC3cXkvFKgurk%3D 20196732
42. GL Hortin 2006 The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome Clin Chem 52 7 1223 1237 10.1373/clinchem.2006.069252 1:CAS:528:DC%2BD28Xms1WmsLY%3D 16644871
43. X Lai, et al. 2009 A proteomic workflow for discovery of serum carrier protein-bound biomarker candidates of alcohol abuse using LC-MS/MS Electrophoresis 30 12 2207 2214 10.1002/elps.200800775 1:CAS:528: DC%2BD1MXosVWksr0%3D 19544491
44. MF Lopez, et al. 2005 High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures Clin Chem 51 10 1946 1954 10.1373/clinchem.2005.053090 1:CAS:528:DC%2BD2MXhtVGmtbjF 16081505
45. MS Lowenthal, et al. 2005 Analysis of albumin-associated peptides and proteins from ovarian cancer patients Clin Chem 51 10 1933 1945 10.1373/clinchem.2005.052944 1:CAS:528:DC%2BD2MXhtVGmtbjE 16099937
46. C Fredolini, et al. 2009 Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH Drug Test Anal 1 9-10 447 454 10.1002/dta.96 1:CAS:528:DC%2BC3cXnsFWktA%3D%3D 20355230
47. C Longo, et al. 2009 Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers PLoS One 4 3 e4763 10.1371/journal.pone.0004763 19274087
48. A Luchini, et al. 2008 Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation Nano Lett 8 1 350 361 10.1021/nl072174l 1:CAS:528:DC%2BD2sXhsVWgu7zN 18076201
49. W Kolch H Mischak AR Pitt 2005 The molecular make-up of a tumour: proteomics in cancer research Clin Sci 108 5 369 383 10.1042/CS20050006 1:CAS:528:DC%2BD2MXjsVGrtrs%3D 15831087
50. PA Everley BR Zetter 2005 Proteomics in tumor progression and metastasis Ann N Y Acad Sci 1059 1 10 10.1196/annals.1339.001 1:CAS:528: DC%2BD28XhvFGntrs%3D 16382037
51. M Ahram, et al. 2002 Proteomic analysis of human prostate cancer Mol Carcinog 33 1 9 15 10.1002/mc.10019 1:CAS:528:DC%2BD38Xmt1yjtg%3D%3D 11807953
52. PH O'Farrell 1975 High resolution two-dimensional electrophoresis of proteins J Biol Chem 250 10 4007 4021 236308
53. K Kleparnik P Bocek 2010 Electrophoresis today and tomorrow: helping biologists' dreams come true Bioessays 32 3 218 226 10.1002/bies.200900152 1:CAS:528:DC%2BC3cXksFCrsbk%3D 20127703
54. A Gorg W Weiss MJ Dunn 2004 Current two-dimensional electrophoresis technology for proteomics Proteomics 4 12 3665 3685 10.1002/pmic.200401031 15543535
55. B Martin, et al. 2008 Biological pathways contributing to organ-specific phenotype of brain metastatic cells J Proteome Res 7 3 908 920 10.1021/pr070426d 1:CAS:528:DC%2BD1cXhslWjtbk%3D 18257520
56. H Hatakeyama, et al. 2006 Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer Proteomics 6 23 6300 6316 10.1002/pmic.200600488 1:CAS:528: DC%2BD2sXhsFGmt74%3D 17133371
57. X Han A Aslanian JR Yates III 2008 Mass spectrometry for proteomics Curr Opin Chem Biol 12 5 483 490 10.1016/j.cbpa.2008.07.024 1:CAS:528: DC%2BD1cXht1KgsbjP 18718552
58. S Pan, et al. 2009 Mass spectrometry based targeted protein quantification: methods and applications J Proteome Res 8 2 787 797 10.1021/pr800538n 1:CAS:528:DC%2BD1cXhsFChsLrK 19105742
59. GC McAlister, et al. 2010 Analysis of tandem mass spectra by FTMS for improved large-scale proteomics with superior protein quantification Anal Chem 82 1 316 322 10.1021/ac902005s 1:CAS:528:DC%2BD1MXhsVOhtr%2FM 19938823
60. AT Kicman MC Parkin RK Iles 2007 An introduction to mass spectrometry based proteomics-detection and characterization of gonadotropins and related molecules Mol Cell Endocrinol 260-262 212 227 10.1016/j.mce.2006.02.022 17097803
61. J Wei, et al. 2008 Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation Anticancer Res 28 1A 327 334 1:CAS:528:DC%2BD1cXjslWhtbw%3D 18383865
62. CC Liao, et al. 2010 Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study World J Surg Oncol 8 33 10.1186/1477-7819-8-33 20420661
63. SA Schwartz, et al. 2005 Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry Cancer Res 65 17 7674 7681 1:CAS:528:DC%2BD2MXpslaitbk%3D 16140934
64. J Vydra, et al. 2008 Two-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues BMC Cancer 8 107 10.1186/1471-2407-8-107 18416831
65. M De Bock, et al. 2010 Challenges for biomarker discovery in body fluids using SELDI-TOF-MS J Biomed Biotechnol 2010 906082 20029632
66. Q Wang, et al. 2009 Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer BMC Cancer 9 287 10.1186/1471-2407-9-287 1:CAS:528:DC%2BD1MXntlSjs7o%3D 19689818
67. FM Smith, et al. 2007 Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy Ann Surg 245 2 259 266 10.1097/01.sla.0000245577.68151.bd 17245180
68. FM Qiu, et al. 2009 Mining novel biomarkers for prognosis of gastric cancer with serum proteomics J Exp Clin Cancer Res 28 126 10.1186/1756-9966-28- 126 19740432
69. JM Asara, et al. 2008 A label-free quantification method by MS/MS TIC compared to SILAC and spectral counting in a proteomics screen Proteomics 8 5 994 999 10.1002/pmic.200700426 1:CAS:528:DC%2BD1cXktVeksrg%3D 18324724
70. VM Faca, et al. 2008 Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains PLoS One 3 6 e2425 10.1371/journal.pone.0002425 18560578
71. DY Zhang, et al. 2009 Proteomics, pathway array and signaling network-based medicine in cancer Cell Div 4 20 10.1186/1747-1028-4-20 19863813
72. P Bertone M Snyder 2005 Advances in functional protein microarray technology FEBS J 272 21 5400 5411 10.1111/j.1742-4658.2005.04970.x 1:CAS:528:DC%2BD2MXht1SltLrO 16262682
73. MM Harmsen HJ De Haard 2007 Properties, production, and applications of camelid single-domain antibody fragments Appl Microbiol Biotechnol 77 1 13 22 10.1007/s00253-007-1142-2 1:CAS:528:DC%2BD2sXhtFGgs7bO 17704915
74. D Kastelic, et al. 2009 A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers J Immunol Methods 350 1-2 54 62 10.1016/j.jim.2009.08. 016 1:CAS:528:DC%2BD1MXht1Gnsb7I 19744487
75. DA Hall J Ptacek M Snyder 2007 Protein microarray technology Mech Ageing Dev 128 1 161 167 10.1016/j.mad.2006.11.021 1:CAS:528:DC%2BD2sXmtVWrtg%3D%3D 17126887
76. SJ Osterfeld, et al. 2008 Multiplex protein assays based on real-time magnetic nanotag sensing Proc Natl Acad Sci USA 105 52 20637 20640 10.1073/pnas.0810822105 1:CAS:528:DC%2BD1MXks1GmsA%3D%3D 19074273
77. YY Fei, et al. 2008 A novel high-throughput scanning microscope for label-free detection of protein and small-molecule chemical microarrays Rev Sci Instrum 79 1 013708 10.1063/1.2830286 1:STN:280:DC%2BD1c%2FptV2jug%3D%3D 18248040
78. RL Grubb, et al. 2009 Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures J Proteome Res 8 6 3044 3054 10.1021/pr8009337 1:CAS:528:DC%2BD1MXkvFGqu74%3D 19275204
79. H Tahara, et al. 2009 Emerging concepts in biomarker discovery; the US-Japan workshop on immunological molecular markers in oncology J Transl Med 7 45 10.1186/1479-5876-7-45 19534815
80. C Gulmann, et al. 2009 Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer J Pathol 218 4 514 519 10.1002/path.2561 1:CAS:528:DC%2BD1MXhtVSqu77F 19396842
81. JD Wulfkuhle, et al. 2008 Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy J Proteome Res 7 4 1508 1517 10.1021/pr7008127 1:CAS:528:DC%2BD1cXhslWjtrg%3D 18257519
82. M He MJ Taussig 2001 Single step generation of protein arrays from DNA by cell-free expression and in situ immobilisation (PISA method) Nucleic Acids Res 29 15 E73 10.1093/nar/29.15.e73 1:STN:280:DC%2BD3MvitFCqtw%3D%3D 11470888
83. M He MJ Taussig 2008 Production of protein arrays by cell-free systems Methods Mol Biol 484 207 215 10.1007/978-1-59745-398-1-14 1:CAS:528: DC%2BD1cXhtFSgsL3F 18592182
84. M Sanchez-Carbayo 2010 Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens Tumour Biol 31 2 103 112 10.1007/s13277-009-0014-z 1:CAS:528:DC%2BC3cXktFOisrs%3D 20358423
85. JD Wulfkuhle, et al. 2003 Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays Proteomics 3 11 2085 2090 10.1002/pmic.200300591 1:CAS:528:DC%2BD3sXptFKqtL8%3D 14595806
86. S Nettikadan, et al. 2006 Detection and quantification of protein biomarkers from fewer than 10 cells Mol Cell Proteomics 5 5 895 901 10.1074/mcp.M500350-MCP200 1:CAS:528:DC%2BD28XkslCls74%3D 16489239
87. S Song, et al. 2007 A cancer protein microarray platform using antibody fragments and its clinical applications Mol Biosyst 3 2 151 158 10.1039/b608973a 1:CAS:528:DC%2BD2sXit1Wrt7k%3D 17245494
88. PM Palagi, et al. 2006 Proteome informatics I: bioinformatics tools for processing experimental data Proteomics 6 20 5435 5444 10.1002/pmic.200600273 1:CAS:528:DC%2BD28XhtFyms7bN 16991191
89. M Blueggel D Chamrad HE Meyer 2004 Bioinformatics in proteomics Curr Pharm Biotechnol 5 1 79 88 10.2174/1389201043489648 1:CAS:528: DC%2BD2cXivVSks7w%3D 14965211
90. NC Tan, et al. 2009 Application of multiple statistical tests to enhance mass spectrometry-based biomarker discovery BMC Bioinformatics 10 144 10.1186/1471-2105-10-144 19442303
91. Y Wang R Hanley RL Klemke 2006 Computational methods for comparison of large genomic and proteomic datasets reveal protein markers of metastatic cancer J Proteome Res 5 4 907 915 10.1021/pr050390u 1:CAS:528:DC%2BD28Xit1elurs%3D 16602698
92. L Beretta 2007 Proteomics from the clinical perspective: many hopes and much debate Nat Methods 4 10 785 786 10.1038/nmeth1007-785 1:CAS:528: DC%2BD2sXhtV2mtr%2FF 17901867
93. V Espina, et al. 2008 A portrait of tissue phosphoprotein stability in the clinical tissue procurement process Mol Cell Proteomics 7 10 1998 2018 10.1074/mcp.M700596-MCP200 1:CAS:528:DC%2BD1cXht1Ols7zL 18667411